Trial intelligence / Profile preview

Phase 2 single-arm study of venetoclax + azacitidine + cytarabine in newly diagnosed MDS-transformed AML

ChiCTR2100051119Phase 2Recruiting

Sponsor

First Affiliated Hospital, Zhejiang University School of Medicine

Start

Oct 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules

Countries

1